Clinical Trial Update: Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 pilot study evaluating autologous T lymphocytes with antibody-dependent cellular cytotoxicity in CD20-positive B-cell malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Snippet

Sponsor: National University Hospital, Singapore | Conditions: B-Cell Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN